← Back to patent-cliff list
CBP-1019
Tier C — Watch / tradeCBP-1019
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：DNA topoisomerase, FOLR1, TRPV6
Indications (approved)：Lung cancer, Colorectal cancer, Breast cancer, Oesophageal cancer, Pancreatic cancer, Solid tumour, Ovarian cancer, Genitourinary neoplasm
Regional status
US
Phase II
2023-01-18
EU
-
China
Phase II
2023-03-14
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of CBP-1019?
Approved indications include: Lung cancer, Colorectal cancer, Breast cancer, Oesophageal cancer, Pancreatic cancer, Solid tumour, Ovarian cancer, Genitourinary neoplasm.
When does the CBP-1019 patent expire?
No public expiry year is available for CBP-1019 yet; this page updates once verified.
How do I get a quote for CBP-1019 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-22